cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25824/redu/ixqktj
title: Influência da exposição de receptores radiográficos digitais à luz ambiente na detecção de reabsorção radicular interna

description: Este conjunto de dados contém planilhas referentes às respostas dos avaliadores sobre a presença ou ausência de reabsorção radicular interna em radiografias obtidas com placas de fósforo fotoestimulável (PSP) submetidas à exposição à luz ambiente após a exposição radiográfica, mas antes do escaneamento. O estudo envolveu três sistemas de PSP: Express, VistaScan e CS7600. As planilhas apresentam os resultados das respostas dos avaliadores para cada condição experimental: exposição à luz (0, 5 ou 10s) e condição de aprimoramento digital (com ou sem) para cada sistema de PSP. Os dados utilizados para o cálculo das concordâncias intra e interexaminador também são apresentados.
DOI: 10.21979/n9/nj1kja
title: Video stimuli for: Adult-to-infant neural coupling mediates infants’ selection of socially-relevant stimuli for learning across cultures

description: See readme for experiment video.pdf for description
DOI: 10.5281/zenodo.18337598
title: Physicochemical data
DOI: 10.5281/zenodo.18337599
title: Physicochemical data
DOI: 10.25824/redu/jmcadw
title: Avaliação da influência de artefatos provenientes de implantes dentários no diagnóstico de reabsorção radicular interna em tomografia computadorizada de feixe cônico

description: Este conjunto de dados contém planilhas referentes às respostas dos avaliadores sobre a presença ou ausência de reabsorção radicular interna (RRI) em imagens de tomografia computadorizada de feixe cônico (TCFC) obtidas em dois aparelhos (Axeos e X1) em diferentes posições e composições de implantes dentários. Os dados deram origem a dois estudos. Os dados referentes ao primeiro estudo encontram-se na planilha "Data" e do segundo estudo na planilha "Data (1)". As planilhas apresentam os resultados das respostas dos avaliadores para cada condição experimental.
DOI: 10.15468/dl.4hwj9u
title: Occurrence Download

description: A dataset containing 121330588 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is United States of America",
 {
 "or" : [
 {
 "not" : {
 "GadmGid" : [
 "is USA"
 ]
 }
 },
 "GadmGid is null"
 ]
 }
 ]
}

 The dataset includes 121330588 records from 5968 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0004740-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.2908/prc_colc_ppsm
title: Purchasing Power Parities outside the European Union (Duty stations) - index (Brussels = 1), monthly data
title: Kaufkraftparitäten außerhalb der Europäischen Union (Dienstorten) - Index (Belgien = 1), monatliche Daten
title: Parités de pouvoirs d'achats hors Union européenne (Lieux d'affectation) - indice (Belgique = 1), données mensuelles
DOI: 10.6084/m9.figshare.29062266
title: A genome-wide association study using HapMap cell lines reveals modulators of cellular response to cyclophosphamide

description: This study identifies single-nucleotide polymorphisms (SNPs) associated with cellular response to cyclophosphamide (CTX) using phosphoramide mustard (PM), its primary cytotoxic metabolite, and explores the downstream consequences for breast cancer (BC) patients. We analyzed 1,978,545 SNPs from EBV-transformed lymphoblastic cell lines (LCLs) derived from 53 unrelated European individuals, in a genome-wide association study using cellular PM sensitivity data. We filtered SNPs associated with PM sensitivity (<i>p</i> &lt; 5 × 10<sup>−5</sup>) predicted to overlap with regulatory elements in breast tissue using a chromatin state prediction model. We then assessed the consequences using LCL transcriptomic data and data from BC patients treated with (ACT-BC; <i>N</i> = 155) and without CTX. Twenty SNPs were filtered out including rs12408401, which was associated with PM resistance (<i>p</i> = 3.89 × 10<sup>−5</sup>), potentially disrupted a CTCF-loop, and was associated with increased <i>RFX5</i> expression (<i>p</i> = 0.036), which was associated with poor disease-free interval in ACT-BC patients (HR = 5.32; <i>p</i> = 0.028); and rs784562, which was associated with improved PM sensitivity (<i>p</i> = 6.41 × 10<sup>−6</sup>), potentially altered nearby enhancer functionality, and reduced expression of <i>KRT72</i> which was associated with poor progression-free survival in ACT-BC patients (HR = 3.61; <i>p</i> = 0.040). Our study identifies SNPs significantly associated with cellular CTX response with potential mechanistic and clinical relevance, thereby providing insights toward optimized CTX treatment strategies.
DOI: 10.6084/m9.figshare.29062266.v1
title: A genome-wide association study using HapMap cell lines reveals modulators of cellular response to cyclophosphamide

description: This study identifies single-nucleotide polymorphisms (SNPs) associated with cellular response to cyclophosphamide (CTX) using phosphoramide mustard (PM), its primary cytotoxic metabolite, and explores the downstream consequences for breast cancer (BC) patients. We analyzed 1,978,545 SNPs from EBV-transformed lymphoblastic cell lines (LCLs) derived from 53 unrelated European individuals, in a genome-wide association study using cellular PM sensitivity data. We filtered SNPs associated with PM sensitivity (<i>p</i> &lt; 5 × 10<sup>−5</sup>) predicted to overlap with regulatory elements in breast tissue using a chromatin state prediction model. We then assessed the consequences using LCL transcriptomic data and data from BC patients treated with (ACT-BC; <i>N</i> = 155) and without CTX. Twenty SNPs were filtered out including rs12408401, which was associated with PM resistance (<i>p</i> = 3.89 × 10<sup>−5</sup>), potentially disrupted a CTCF-loop, and was associated with increased <i>RFX5</i> expression (<i>p</i> = 0.036), which was associated with poor disease-free interval in ACT-BC patients (HR = 5.32; <i>p</i> = 0.028); and rs784562, which was associated with improved PM sensitivity (<i>p</i> = 6.41 × 10<sup>−6</sup>), potentially altered nearby enhancer functionality, and reduced expression of <i>KRT72</i> which was associated with poor progression-free survival in ACT-BC patients (HR = 3.61; <i>p</i> = 0.040). Our study identifies SNPs significantly associated with cellular CTX response with potential mechanistic and clinical relevance, thereby providing insights toward optimized CTX treatment strategies.
DOI: 10.6084/m9.figshare.28955838
title: A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS)

description: Combination treatment with an anti-programmed cell death-1 (PD-1) antibody, an immune checkpoint inhibitor (ICI), and chemotherapy is the standard treatment for patients with HER2-negative advanced gastric/esophagogastric cancer (AGC). ICI re-administration has been reported to have a clinical benefit for patients with lung cancer or melanoma. However, data on patients with AGC have not yet been collected. We plan to conduct a prospective, multicenter, observational NIVO RETURNS study to evaluate the efficacy and safety of nivolumab monotherapy re-administration in patients with AGC refractory to initial anti-PD-1 or anti-programmed cell death ligand-1 (PD-L1) antibody treatment. Patients who have achieved clinical benefits (complete response, partial response, or stable disease for ≥ 6 months) from prior treatment, including anti-PD-1/PD-L1 therapy, will be included. The primary endpoint will be the objective response rate to nivolumab re-administration. We anticipate that our findings will contribute to the improvement of survival outcomes as later-line treatment for AGC. <b>Clinical trial registration:</b> UMIN000050515, UMIN000051044. Patients with advanced gastric or esophagogastric cancer that does not have the HER2 protein are usually treated with a combination of chemotherapy and a type of immunotherapy called an anti-PD-1 antibody. This treatment helps the immune system fight the cancer. However, even if the treatment works at first, the cancer often comes back or stops responding. In some cancers like lung cancer and melanoma, repeating immunotherapy after a break – called re-administration – has shown positive results. But for gastric cancer, there is little information about whether this strategy is helpful. We are planning a research study called the NIVO RETURNS study. It will take place at multiple hospitals and will follow patients over time without changing their treatment plans. The goal is to see if re-administering a drug called nivolumab (an anti-PD-1 antibody) is effective and safe in patients with advanced gastric cancer who were previously treated with similar drugs. We will include patients whose cancer responded well to earlier treatment (such as tumor shrinkage or disease stability for 6 months or more). The main outcome we will measure is how many patients show a positive response to nivolumab re-administration. We hope that this study will help doctors better understand whether restarting immunotherapy can be a useful option for patients with few remaining treatments. Ultimately, we aim to improve the survival and quality of life for people with advanced gastric cancer.
DOI: 10.6084/m9.figshare.28955838.v1
title: A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS)

description: Combination treatment with an anti-programmed cell death-1 (PD-1) antibody, an immune checkpoint inhibitor (ICI), and chemotherapy is the standard treatment for patients with HER2-negative advanced gastric/esophagogastric cancer (AGC). ICI re-administration has been reported to have a clinical benefit for patients with lung cancer or melanoma. However, data on patients with AGC have not yet been collected. We plan to conduct a prospective, multicenter, observational NIVO RETURNS study to evaluate the efficacy and safety of nivolumab monotherapy re-administration in patients with AGC refractory to initial anti-PD-1 or anti-programmed cell death ligand-1 (PD-L1) antibody treatment. Patients who have achieved clinical benefits (complete response, partial response, or stable disease for ≥ 6 months) from prior treatment, including anti-PD-1/PD-L1 therapy, will be included. The primary endpoint will be the objective response rate to nivolumab re-administration. We anticipate that our findings will contribute to the improvement of survival outcomes as later-line treatment for AGC. <b>Clinical trial registration:</b> UMIN000050515, UMIN000051044. Patients with advanced gastric or esophagogastric cancer that does not have the HER2 protein are usually treated with a combination of chemotherapy and a type of immunotherapy called an anti-PD-1 antibody. This treatment helps the immune system fight the cancer. However, even if the treatment works at first, the cancer often comes back or stops responding. In some cancers like lung cancer and melanoma, repeating immunotherapy after a break – called re-administration – has shown positive results. But for gastric cancer, there is little information about whether this strategy is helpful. We are planning a research study called the NIVO RETURNS study. It will take place at multiple hospitals and will follow patients over time without changing their treatment plans. The goal is to see if re-administering a drug called nivolumab (an anti-PD-1 antibody) is effective and safe in patients with advanced gastric cancer who were previously treated with similar drugs. We will include patients whose cancer responded well to earlier treatment (such as tumor shrinkage or disease stability for 6 months or more). The main outcome we will measure is how many patients show a positive response to nivolumab re-administration. We hope that this study will help doctors better understand whether restarting immunotherapy can be a useful option for patients with few remaining treatments. Ultimately, we aim to improve the survival and quality of life for people with advanced gastric cancer.
DOI: 10.6084/m9.figshare.29244396
title: Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma

description: Limited data exist regarding dedifferentiated liposarcoma (DDLPS) treatment, biomarker frequency, and clinical outcomes. Additional epidemiological data are needed to inform clinical trial design for testing novel therapeutics. Retrospective data from a US-based deidentified clinico-genomic database were analyzed for patients treated for metastatic DDLPS between 2011 and 2021. Overall survival (OS), real-world progression-free survival (rwPFS), and time to next treatment (TTNT) were described in the overall cohort (<i>n</i> = 51) and in a subgroup of patients with murine double minute 2 (<i>MDM2</i>) amplification and wild-type tumor protein p53 (<i>TP53</i> WT) (<i>n</i> = 38, 74.5%). Patients had a median age of 64.8 years, and 62.7% were male. The most common first-line treatment was doxorubicin with olaratumab (23.5%). From time of first-line (1 L) treatment, median OS for the entire cohort and <i>MDM2</i>-amplified, <i>TP53</i> WT subgroup was 12.6 and 11.7 months, respectively; median rwPFS was 2.5 months for both. Median TTNT was 3.9 months for the full cohort and 4.8 months for the <i>MDM2</i>-amplified, <i>TP53</i> WT subgroup. The descriptive analysis here contributes real-world data describing treatment patterns, biomarker status, and clinical outcomes for patients with DDLPS, an aggressive and poorly characterized form of LPS with limited treatment options. Researchers have been looking into a rare and aggressive cancer called dedifferentiated liposarcoma (DDLPS) to better understand how it’s treated, what genetic markers are involved, and how patients fare with current treatments. They studied medical records covering the years 2011–2021 from a large US database, focusing on patients who received treatment for DDLPS that had spread to other parts of the body. The study included 51 patients, with a significant portion having a specific genetic feature (murine double minute 2 [<i>MDM2</i>] gene amplification) and a normal version of another gene (wild-type tumor protein p53 [<i>TP53</i> WT]). Most patients were around 65 years old and predominantly male. The most common initial treatment was a combination of doxorubicin and olaratumab. The researchers found that patients lived about 12.6 months after starting treatment, with survival being slightly shorter, about 11.7 months, for those having the specific genetic feature. Patients typically did not see their cancer progress for about 2.5 months, and it took around 3.9–4.8 months before they needed a new treatment. This study helps fill in some gaps about DDLPS by showing what treatments are being used and how patients are doing, which could help in designing future clinical trials for new treatments.
DOI: 10.6084/m9.figshare.29244396.v1
title: Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma

description: Limited data exist regarding dedifferentiated liposarcoma (DDLPS) treatment, biomarker frequency, and clinical outcomes. Additional epidemiological data are needed to inform clinical trial design for testing novel therapeutics. Retrospective data from a US-based deidentified clinico-genomic database were analyzed for patients treated for metastatic DDLPS between 2011 and 2021. Overall survival (OS), real-world progression-free survival (rwPFS), and time to next treatment (TTNT) were described in the overall cohort (<i>n</i> = 51) and in a subgroup of patients with murine double minute 2 (<i>MDM2</i>) amplification and wild-type tumor protein p53 (<i>TP53</i> WT) (<i>n</i> = 38, 74.5%). Patients had a median age of 64.8 years, and 62.7% were male. The most common first-line treatment was doxorubicin with olaratumab (23.5%). From time of first-line (1 L) treatment, median OS for the entire cohort and <i>MDM2</i>-amplified, <i>TP53</i> WT subgroup was 12.6 and 11.7 months, respectively; median rwPFS was 2.5 months for both. Median TTNT was 3.9 months for the full cohort and 4.8 months for the <i>MDM2</i>-amplified, <i>TP53</i> WT subgroup. The descriptive analysis here contributes real-world data describing treatment patterns, biomarker status, and clinical outcomes for patients with DDLPS, an aggressive and poorly characterized form of LPS with limited treatment options. Researchers have been looking into a rare and aggressive cancer called dedifferentiated liposarcoma (DDLPS) to better understand how it’s treated, what genetic markers are involved, and how patients fare with current treatments. They studied medical records covering the years 2011–2021 from a large US database, focusing on patients who received treatment for DDLPS that had spread to other parts of the body. The study included 51 patients, with a significant portion having a specific genetic feature (murine double minute 2 [<i>MDM2</i>] gene amplification) and a normal version of another gene (wild-type tumor protein p53 [<i>TP53</i> WT]). Most patients were around 65 years old and predominantly male. The most common initial treatment was a combination of doxorubicin and olaratumab. The researchers found that patients lived about 12.6 months after starting treatment, with survival being slightly shorter, about 11.7 months, for those having the specific genetic feature. Patients typically did not see their cancer progress for about 2.5 months, and it took around 3.9–4.8 months before they needed a new treatment. This study helps fill in some gaps about DDLPS by showing what treatments are being used and how patients are doing, which could help in designing future clinical trials for new treatments.
DOI: 10.15468/dd.9gesq6
title: Dataset generated from Esri tool

description: Derived dataset generated by Esri geoprocessing tool using GBIF API
DOI: 10.6084/m9.figshare.29264656
title: Clinical features and outcomes of first-line EGFR-TKI treatment in younger and older patients with EGFR-mutated NSCLC

description: The clinical characteristics and outcomes of younger versus older patients with EGFR-mutated advanced NSCLC undergoing first-line EGFR-TKI treatment remain underexplored. This multicenter, retrospective study analyzed patients treated between 2010 and 2019. Univariate and multivariate analyses identified factors associated with outcomes. Among 235 patients, 38 were under 50 years and 197 over 65 years. Median progression-free survival (PFS) was 21.1 months in younger patients and 15.6 months in older patients (<i>p</i> = 0.095). Median overall survival (OS) was 40.0 months in the young group and 23.2 months in the elderly group (<i>p</i> = 0.008). Afatinib or erlotinib was linked to longer OS in younger patients. In elderly patients, better ECOG performance status and body mass index over 18.5 were significantly associated with improved OS. Younger patients receiving afatinib or erlotinib showed better outcomes. For older patients, clinical factors such as functional status and body weight strongly influenced survival.
DOI: 10.6084/m9.figshare.29264656.v1
title: Clinical features and outcomes of first-line EGFR-TKI treatment in younger and older patients with EGFR-mutated NSCLC

description: The clinical characteristics and outcomes of younger versus older patients with EGFR-mutated advanced NSCLC undergoing first-line EGFR-TKI treatment remain underexplored. This multicenter, retrospective study analyzed patients treated between 2010 and 2019. Univariate and multivariate analyses identified factors associated with outcomes. Among 235 patients, 38 were under 50 years and 197 over 65 years. Median progression-free survival (PFS) was 21.1 months in younger patients and 15.6 months in older patients (<i>p</i> = 0.095). Median overall survival (OS) was 40.0 months in the young group and 23.2 months in the elderly group (<i>p</i> = 0.008). Afatinib or erlotinib was linked to longer OS in younger patients. In elderly patients, better ECOG performance status and body mass index over 18.5 were significantly associated with improved OS. Younger patients receiving afatinib or erlotinib showed better outcomes. For older patients, clinical factors such as functional status and body weight strongly influenced survival.
DOI: 10.6084/m9.figshare.30610387
title: Pre-irradiation administration of nilestriol promotes hematopoietic recovery but increases early mortality risk and impairs wound healing after total-body irradiation combined with wound trauma

description: Estrogens are frequently employed as radioprotective agents in nuclear emergencies, yet their effects on radiation combined injury (RCI) are poorly understood. This study evaluated the impact of nilestiol on radiation-wound combined injury (R-W-CI). Mouse models included 6.0 and 8.0 Gy total body irradiation (TBI), 2.0% of the total body surface area (TBSA) skin wound trauma, and R-W-CI (6.0 or 8.0 Gy TBI followed by a 2% TBSA wound). Nilestriol was administered 3 and 1 day pre-injury. The outcomes assessed included 30-day survival, weight changes, peripheral blood analysis, wound closure, bone marrow-derived clonogenic activity, flow cytometric analysis of hematopoietic stem and progenitor cells, and splenic extramedullary hematopoiesis. Nilestriol significantly improved 30-day survival rate in mice subjected to 8.0 Gy TBI and enhanced hematopoietic recovery in those exposed to 6.0 Gy TBI. In wound-only models, nilestriol suppressed early inflammatory cytokines and impaired wound closure. For R-W-CI model with 8.0 Gy, nilestriol significantly improved the 30-day survival rate but increased the risk of early mortality. For R-W-CI with 6.0 Gy, nilestriol significantly promoted hematopoietic recovery, but led to a significant delay in wound healing by more pronounced inhibitory effects on the early inflammatory response in wounds of R-W-CI. No gender differences were observed in the effects of nilestriol. Additionally, Splenic extramedullary hematopoiesis was inhibited in nilestriol pretreatment groups. These findings suggest that pre-irradiation administration of nilestriol can mitigate R-W-CI effects but requires careful consideration due to potential negative impacts on both systemic and local levels.